Sun, Haoping <br/><br/>
Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease.  [electronic resource] 

 -  Journal of autoimmunity  Nov 2017 
 - 97-108 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1095-9157 
<br/><br/><label>Standard No.: </label>10.1016/j.jaut.2017.08.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Cells, Cultured<br/>Complement C1q--immunology<br/>Complement C3--metabolism<br/>Complement System Proteins--immunology<br/>Cytotoxicity, Immunologic<br/>Disease Models, Animal<br/>Erythrocytes--physiology<br/>Glomerulonephritis, Membranous<br/>Hemolysis<br/>Humans<br/>Immune System Diseases--immunology<br/>Immunoglobulin Fc Fragments--genetics<br/>Immunoglobulin G--genetics<br/>Molecular Targeted Therapy<br/>Protein Binding<br/>Protein Multimerization<br/>Receptors, Fc--metabolism<br/>Thy-1 Antigens--immunology<br/>Transgenes--genetics